Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosentyx in Adult Onset Pityriasis Rubra Pilaris
NCT03342573Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of secukinumab in pityriasis rubra pilaris (PRP), sponsored by Mayo Clinic. Primary endpoint: Psoriasis Area and Severity Index 75% Reduction at 28 weeks. Started Apr 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
pityriasis rubra pilaris (PRP)
Beyond the preview
Go deeper on NCT03342573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342573.